Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib + gemcitabine versus gemcitabine alone for recurrent or metastatic cervical cancer
ChiCTR1900020912Phase 2Not yet recruiting
- Sponsor
- The First People's Hospital of Yueyang
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of anlotinib and gemcitabine in Cervical Cancer (CC) (2 arms), sponsored by The First People's Hospital of Yueyang. Primary endpoints: Objective response rate and Disease control rate. Planned start Jun 2019; status: not yet recruiting.
02
Drugs
anlotinibgemcitabine
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR1900020912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900020912.